Name (Synonyms) | Correlation | |
---|---|---|
drug1003 | Goal Management Training (GMT) Wiki | 1.00 |
drug1534 | Muse headband with Myndlift app Wiki | 1.00 |
drug1173 | IgM and IgG diagnostic kits to SARS-CoV-2 Wiki | 1.00 |
There is one clinical trial.
During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19. In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit. Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries. We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study. The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa. Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.
Description: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Measure: Positive IgM/IgG tests Time: At inclusionDescription: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Measure: Positive IgM/IgG tests Time: 1 monthDescription: Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Measure: Positive IgM/IgG tests Time: 5 monthDescription: Comparison of the resultat from the point of care test and with results from Elisa
Measure: Comparison of the point of care test and Elisa Time: At inclusionDescription: Comparison of the resultat from the point of care test and with results from Elisa
Measure: Comparison of the point of care test and Elisa Time: 1 monthsDescription: Comparison of the resultat from the point of care test and with results from Elisa
Measure: Comparison of the point of care test and Elisa Time: 5 monthsDescription: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19
Measure: Re-infection rate Time: 180 daysDescription: Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19
Measure: Re-infection rate Time: 360 daysDescription: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up
Measure: IgM/IgG positive participants on follow-up test Time: 1 monthDescription: Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up
Measure: IgM/IgG positive participants on follow-up test Time: 5 months